PBPIA
AVTX icon

Pivotal bioVenture Partners Investment Advisor’s Avalo Therapeutics AVTX Stock Holding History

Pivotal bioVenture Partners Investment Advisor’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.42M Buy
+295,933
New +$4.63M 1.58% 10

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's AVTX Position: Q1 2026 in Review

Pivotal bioVenture Partners Investment Advisor opened a new position in Avalo Therapeutics (AVTX) in Q1 2026: 295,933 shares worth $4.42M. The stake represents 1.58% of the portfolio and ranks #10 among its holdings.

97 funds tracked by Wall St. Rank hold AVTX as of Q1 2026.

  • Pivotal bioVenture Partners Investment Advisor held 295,933 shares of Avalo Therapeutics worth $4.42M as of Q1 2026.
  • Avalo Therapeutics was a new Pivotal bioVenture Partners Investment Advisor position in Q1 2026.
  • Avalo Therapeutics made up 1.58% of Pivotal bioVenture Partners Investment Advisor's portfolio in Q1 2026, its #10 holding.
  • 97 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q1 2026.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.